Page last updated: 2024-11-05

visnagin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Visnagin is a naturally occurring coumarin derivative isolated from the Egyptian plant Ammi visnaga. It has been studied for its potential medicinal properties, particularly as a vasodilator and antispasmodic agent. Its synthesis is achievable through various organic chemistry methods involving modifications of the coumarin core structure. Visnagin's effects include smooth muscle relaxation, vasodilation, and anti-inflammatory actions. Its importance lies in its potential therapeutic use in conditions like angina, asthma, and other circulatory disorders. Research focuses on understanding its mechanisms of action, optimizing its pharmacological properties, and exploring its potential as a drug candidate.'

visnagin: from Musineon divaricatum [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

visnagin : A furanochromone that is furo[3,2-g]chromen-5-one which is substituted at positions 4 and 7 by methoxy and methyl groups, respectively. Found in the toothpick-plant, Ammi visnaga. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
AmmigenusA plant genus of the family APIACEAE that is the primary plant source of KHELLIN.[MeSH]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]
Musineongenus[no description available]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]
Musineon divaricatumspecies[no description available]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]

Cross-References

ID SourceID
PubMed CID6716
CHEMBL ID45176
CHEBI ID10002
SCHEMBL ID498450
MeSH IDM0131076

Synonyms (84)

Synonym
4-methoxy-7-methyl-furo[3,2-g]chromen-5-one
bdbm50051349
BRD-K68995359-001-02-8
gtpl433
4-methoxy-7-methylpyrano[3,2-f][1]benzoxol-5-one
DIVK1C_006549
KBIO1_001493
SDCCGMLS-0066603.P001
SPECTRUM_001227
SPECTRUM4_001766
einecs 201-430-3
4-methoxy-7-methylfuro(3,2-g)chromen-5-one
5h-furo(3,2-g)(1)benzopyran-5-one, 4-methoxy-7-methyl-
brn 0234955
nsc 100593
4-methoxy-7-methyl-5h-furo(3,2-g)(1)-benzopyran-5-one
SPECTRUM5_000351
BSPBIO_003099
NCGC00178297-01
OPREA1_854963
MEGXP0_000332
nsc-100593
visnagine
visnagin
desmethoxykhellin
82-57-5
visnagidin
5-methoxy-2-methylfuranochromone
nsc100593
5h-furo[3, 4-methoxy-7-methyl-
C09049
MLS000697721
smr000112234
NCGC00095626-01
KBIOSS_001707
KBIO2_004275
KBIO2_006843
KBIO2_001707
KBIO3_002319
KBIOGR_002251
SPECPLUS_000453
SPECTRUM3_001340
SPECTRUM2_001796
SPBIO_001751
SPECTRUM310041
LMPK13110003
nzvqlvgozreltg-uhfffaoysa-
inchi=1/c13h10o4/c1-7-5-9(14)12-11(17-7)6-10-8(3-4-16-10)13(12)15-2/h3-6h,1-2h3
chebi:10002 ,
CHEMBL45176 ,
4-methoxy-7-methylfuro[3,2-g]chromen-5-one
L000822
NCGC00095626-02
AKOS015955735
HMS2268P15
CCG-38444
5-19-06-00030 (beilstein handbook reference)
p64438mlbw ,
unii-p64438mlbw
FT-0603293
STL372894
4-methoxy-7-methyl-5h-furo[3,2-g]chromen-5-one ,
4-methoxy-7-methyl-5h-furo(3,2-g)(1)benzopyran-5-one
visnagin [mi]
5h-furo[3,2-g][1]benzopyran-5-one,4-methoxy-7-methyl-
BBL027492
DTXSID50231509
SCHEMBL498450
fuk-724
4-methoxy-7-methyl-5h-furo[3,2-g]-1-benzopyran-5-one
5h-furo[3,2-g][1]benzopyran-5-one, 4-methoxy-7-methyl-
4-methoxy-7-methyl-5h-furo[3,2-g]chromen-5-one #
sr-01000765669
SR-01000765669-3
SR-01000765669-4
VS-08551
Q7936365
desmethoxykhellin; nsc 100593; visnagidin; visnagine
BRD-K68995359-001-06-9
CS-0016370
HY-N1082
mfcd00005008
4-methoxy-7-methyl-5h-furo[3,2-g][1]benzopyran-5-one
EN300-6745554

Research Excerpts

Overview

Visnagin (VIS) is a furanochromone and one of the main compounds of Ammi visnaga L. It has promising antioxidant and anti-inflammatory effects. Its protective efficacy against Pb toxicity has not been investigated.

ExcerptReferenceRelevance
"Visnagin (VIS) is a natural bioactive component of Ammi visnaga, with promising radical scavenging and anti-inflammatory activities."( Visnagin prevents isoproterenol-induced myocardial injury by attenuating oxidative stress and inflammation and upregulating Nrf2 signaling in rats.
Abukhalil, MH; Al-Amarat, W; Al-Swailmi, FK; Aladaileh, SH; Alanazi, KM; Alfwuaires, MA; Algefare, AI; Althunibat, OY; Hussein, OE; Kamel, EM; Mahmoud, AM; Saghir, SA, 2021
)
2.79
"Visnagin is a furanochromone and one of the main compounds of Ammi visnaga L. "( Visnagin ameliorates myocardial ischemia/reperfusion injury through the promotion of autophagy and the inhibition of apoptosis.
Feng, BB; Fu, HR; Li, XS; Pan, LH; Zhang, YH, 2020
)
3.44
"Visnagin (VIS) is a furanochromone with promising antioxidant and anti-inflammatory effects; however, its protective efficacy against Pb toxicity has not been investigated."( Effect of Visnagin on Altered Steroidogenesis and Spermatogenesis, and Testicular Injury Induced by the Heavy Metal Lead.
Ajarem, JS; Allam, AA; Allam, GA; Hegazy, AK; Mahmoud, AM; Maodaa, SN, 2021
)
1.75

Pharmacokinetics

The aim of the present study was to evaluate the pharmacokinetic properties of visnagin and an aqueous Ammi visnaga extract after oral administration in rats.

ExcerptReferenceRelevance
" To date, no information is available about the pharmacokinetic (PK) properties of visnagin."( Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration.
Butterweck, V; Haug, KG; Hochhaus, G; Weber, B, 2012
)
0.89
" After determination of the pharmacokinetic properties of visnagin after intravenous bolus administration in rats, the aim of the present study was to evaluate the pharmacokinetic properties of visnagin and an aqueous Ammi visnaga extract after oral administration in rats."( Pharmacokinetic evaluation of visnagin and Ammi visnaga aqueous extract after oral administration in rats.
Butterweck, V; Haug, KG; Hochhaus, G; Weber, B, 2012
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
phytotoxinAny toxin produced by a plant.
EC 1.1.1.37 (malate dehydrogenase) inhibitorAn EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of any malate dehydrogenase (EC 1.1.1.37).
vasodilator agentA drug used to cause dilation of the blood vessels.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
furanochromoneAn organic heterotricyclic compound that is chromone which is ortho-fused to a furan ring and its substituted derivatives thereof.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency141.25400.010039.53711,122.0200AID1479
mitogen-activated protein kinase 1Homo sapiens (human)Potency1.99530.039816.784239.8107AID995
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.16230.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency39.81071.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)Ki60.00000.00000.930610.0000AID34709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1345618Human A2A receptor (Adenosine receptors)1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.
AID1345822Human A3 receptor (Adenosine receptors)1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID34709Binding affinity against human adenosine A3 receptor in HEK293 cells using [125I]AB-MECA 21680 radioligand.1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID33195Ability to displace [125I]-AB-MECA binding from adenosine A3 receptor.1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model.
AID231110Ratio of binding affinities between rA1 and rA3 of rat striatal membrane.1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.
AID31687Percentage inhibition against Adenosine A1 receptor in rat brain membranes using [3H]-PIA1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.
AID33570Binding affinity at Adenosine A2 receptor in rat striatal membranes by [3H]-CGS- 21680 displacement.1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID82013Serum high density lipoprotein (HDL) cholesterol alteration by the compound at 50 mg/kg/day dose in normocholesterolemic Male S.E.A. Japanese quail with 5-7 weeks of age1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Khellin analogues. 1. General topological requirements for lipid-altering activity in furochromones.
AID203650Total Serum HDL cholesterol alteration by the compound at 50 mg/kg/day dose in normocholesterolemic Male S.E.A. Japanese quail with 5-7 weeks of age1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Khellin analogues. 1. General topological requirements for lipid-altering activity in furochromones.
AID203649Serum lipoprotein (VLDL+LDL) cholesterol alteration by the compound at 50 mg/kg/day dose in normocholesterolemic Male S.E.A. Japanese quail with 5-7 weeks of age1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Khellin analogues. 1. General topological requirements for lipid-altering activity in furochromones.
AID33150Ability to displace [3H]-CGS- 21680 binding from adenosine A2A receptor.1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID30343Ability to displace [3H]N6-phenylisopropyladenosine binding from Adenosine A1 receptor.1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (18.75)18.7374
1990's11 (17.19)18.2507
2000's8 (12.50)29.6817
2010's23 (35.94)24.3611
2020's10 (15.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.73 (24.57)
Research Supply Index4.23 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]